Results 91 to 100 of about 54,917 (299)

SGLT2 Inhibitors for Cardioprotection

Oman Medical Journal, 2023
Sulthan Al Rashid, P. Elango, Syed Ziaur Rahman   +2 more
openaire   +3 more sources

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin

, 2015
Jochen SeufertDepartment of Endocrinology and Diabetology, Clinic for Internal Medicine II, Freiburg University Hospital, Freiburg, GermanyAbstract: Despite the availability of a great variety of medications, a significant proportion of people with type ...
Seufert, Jochen, Seufert J
core   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

SGLT2 independent effects of the SGLT2 inhibitor empagliflozin:Focus on the heart [PDF]

This thesis explores how sodium glucose cotransporter 2 inhibitors (SGLT2i), particularly empagliflozin (EMPA), reduce cardiovascular risk by investigating their effects on cardiac infarction, hypertrophy, and heart failure (HF).
Chen, S.
core   +5 more sources

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis

Journal of Infection and Public Health
Background: Tuberculosis (TB) is a widespread infectious disease and is associated with high mortality if not effectively treated. We studied the influence of sodium-glucose cotransporter 2 inhibitors (SGLT2-i) on mortality in patients with TB.
Chung-Shu Lee, Chung-Han Ho, Kuang-Ming Liao, Yu-Cih Wu, Chin-Chung Shu   +4 more
doaj   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

SGLT2 Inhibitors in Cardio-Oncology

JACC: Advances
BACKGROUND: According to available evidence, sodium-glucose cotransporter-2 inhibitors (SGLT2i) may confer cardioprotection in patients with cancer undergoing chemotherapy. OBJECTIVES: The objective of the study was to evaluate the impact of SGLT2i on all-cause mortality and heart failure (HF) outcomes in this population.
Spadafora L., Bernardi M., Sarto G., Simeone B., Rocco E., Carbone S., Dalla Vecchia L. A., Pedretti R. F. E., Valenti V., Di Mario R., Forte M., Frati G., Abbate A., Golino M., Versaci F., Peruzzi M., Sabouret P., Biondi Zoccai G., Sciarretta S.   +18 more
openaire   +3 more sources

SGLT2 억제제의 혈당 강하 효과

, 2014
There are numerous glucose lowering agents in clinical use for type 2 diabetic patients, yet most do not achieve glycemic targets. Recently, inhibitors of the sodium glucose cotransporter 2 (SGLT2) have been developed, which show great potential of being
Kim, HJ
core   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Schematic representation of the effect of SGLT2 on mesangial cells.

, 2016
Glucose enters the cells through both a facilitative glucose transporter (GLUT1) and a sodium-coupled glucose transporter 2 (SGLT2). Na+ entry through SGLT2 according to extracellular glucose concentrations brings about Ca2+ influx through the sodium ...
Masanori Wakisaka (2575552), Tetsuhiko Nagao (2575558), Mototaka Yoshinari (2575555)   +2 more
core   +1 more source